Glucose Management
Glucose management is relevant to ALL critically unwell, whether they are diabetic or not.
-
Patients may be on altered feeding regimes
-
For example, continuous enteral (NG) or parenteral (IV) feeds
-
-
Critical illness is associated with both hyper- and hypoglycaemia
-
Systemic inflammation and stress response, increased metabolic demands, hepatic dysfunction, etc.
-
-
Various pharmacological agents (eg. sedatives) may mask signs and symptoms of hypoglycaemia
Standard glucose target = 6 - 12 mmol/L
-
Tight glucose targets in intensive patients are associated with worse outcomes (NICE-SUGAR trial)
Generally, on admission to ICU, all oral hypoglycaemic agents should be ceased and sugars should be managed with short-acting insulin therapy.
As the patient improves, long acting insulin will be added and/or re-introduction of regular oral hypoglycaemic agents will occur
Patients with new or increased insulin requirements should be referred for endocrine follow-up on discharge from ICU
Hyperglycaemia
Sliding Scale Insulin Regime
-
Interval insulin boluses titrated to target BSL
-
Agent - Novorapid
-
Route - subcutaneous
-
Timing:
-
QID for continuous feeding regimes
-
TDS with meals for ward diet
-
-
Dose
-
Regime:
-
BSL 12.1 - 15 --> 2 - 4 units
-
BSL 15.1 - 18 --> 4 - 6 units
-
BSL > 18 --> 8 - 10 units AND medical team should be notified
-
-
In insulin naive patients, start low
-
In patients with pre-existing insulin resistance, larger dosing regimes may be required
-
Always err on side of caution; additional insulin may be given if required
-
-
Long Acting Insulin
-
Basal insulin regime
-
Provides 24 hour background insulin
-
Often used to transition from insulin infusion in the critically ill
-
-
Agent - Lantus
-
Route - subcutaneous
-
Dose:
-
30 - 60% of 24 hour total dose of short acting insulin
-
Start low and up-titrate as necessary
-
Short-acting insulin doses should be adjusted down accordingly
-
Insulin Infusion
-
Allows rapid and fine control of plasma glucose levels
-
Commence infusion if 2 consecutive BSLs > 12
-
Check with ICU registrar prior to commencing insulin infusion
-
-
Agent - Actrapid
-
Route - Intravenous
-
Dose:
-
Titrated to target BSL as per protocol
-
Must always be run concurrently with dextrose infusion unless patient is receiving continuous enteral feeds or TPN
-
-
Cessation of an infusion may require transition to alternative insulin therapy
-
In patients with T1DM, long acting insulin should be commenced 2 - 4 hours PRIOR to cessation of infusion to avoid development of DKA
-
In patients without T1DM:
-
Commencement of PRN sliding scale following cessation may be adequate
-
If insulin requirements are high (> 4 units/hr) or patient is normally on some form of insulin, long acting insulin may also be necessary
-
-
Hypoglycaemia
Hypoglycaemia is considered a BSL < 3.5 - 4 mmol/L (although there is no strict cut-off)
-
Severe hypoglycaemia = BSL < 3.0 mmol/L
-
In patients with chronic hyperglycaemia, relative hypoglycaemia may even occur at levels in the 4s and 5s
New altered conscious state or delirium should always prompt a check of blood sugar levels
Management:
-
If conscious and able to swallow:
-
Glucogel 15 - 20g AND/OR 150ml juice (make sure it is not sugar free!)
-
Slow release complex carbohydrate; eg. sandwhich
-
In addition to the fast-acting sugar
-
-
-
If not able to swallow or severe hypoglycaemia:
-
25 - 50ml 50% dextrose IV (12.5 - 25g glucose) +/- commence dextrose infusion
-
Glucagon 1 - 2 mg IM, if no intravenous access
-
-
BSL should be checked at 15 minutes, 1 hour and 4 hours
-
Repeat treatment if BSL remains < 4 mmol/L
-
-
Ensure patient is receiving ongoing source of glucose to prevent recurrence
Author: Ryan Slack, Peer Reviewer: Irma Bilgrami Date: 02/04/20